Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Eribulin in HER2-Negative Metastatic Breast Cancer
NCT02481050Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in breast cancer, sponsored by Eisai Co., Ltd.. Started Jun 2015; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02481050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02481050.